id: NEW:psychotropic_analgesic_nitrous_oxide_pan_treatment_to_NEW:time_to_psychological_treatment_entry
name: Psychotropic Analgesic Nitrous Oxide (PAN) Treatment â†’ Time to Psychological
  Treatment Entry
from_node:
  node_id: NEW:psychotropic_analgesic_nitrous_oxide_pan_treatment
  node_name: Psychotropic Analgesic Nitrous Oxide (PAN) Treatment
to_node:
  node_id: NEW:time_to_psychological_treatment_entry
  node_name: Time to Psychological Treatment Entry
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: PAN treatment is administered to patients experiencing alcohol withdrawal
  syndrome, providing rapid therapeutic effects on withdrawal symptoms'
- 'Step 2: PAN therapy requires minimal sedative medication compared to benzodiazepine
  regimens, reducing sedation duration and intensity'
- 'Step 3: Improved psychomotor function is achieved more quickly due to reduced sedative
  load (WMD -8.71 improvement in psychomotor function)'
- 'Step 4: Patients with less sedation and better psychomotor function are cognitively
  and physically prepared to engage in psychological treatment sooner'
- 'Step 5: Time to entry into psychological treatment phase is reduced, accelerating
  overall recovery trajectory'
evidence:
  quality_rating: B
  n_studies: 5
  primary_citation: M A Gillman et al. 2007. Psychotropic analgesic nitrous oxide
    for alcoholic withdrawal states. The Cochrane database of systematic reviews.
  supporting_citations: []
description: Psychotropic analgesic nitrous oxide (PAN) treatment reduces time to
  psychological treatment entry in alcohol withdrawal patients by providing rapid
  symptom improvement while minimizing sedative medication requirements. The reduced
  sedation load preserves psychomotor function, enabling patients to be cognitively
  and physically ready to engage in psychological treatment more quickly than those
  receiving traditional benzodiazepine regimens.
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
quantitative_effects:
  effect_size:
    value: 1.35
    type: relative_risk
    ci_lower: 1.01
    ci_upper: 1.79
  p_value: null
  sample_size: 212
moderators:
- name: withdrawal_severity
  direction: weakens
  strength: moderate
  description: Evidence supports efficacy primarily for mild to moderate alcohol withdrawal
    states; effectiveness in severe cases uncertain
